'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The pharmaceutical firm will work with the health tech company to create a digital therapeutic intended for patients dealing with a breast cancer diagnosis.
A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
The company’s analysis of 2.5m patients worldwide suggest a growing proportion of younger patients, with implications for future study design and deployment.
The US agency has approved Enhertu for patients diagnosed with HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
The agency has approved Lynparza for use in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
The company’s analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
The #BlackDataMatters movement aims to improve outcomes for Black women living with breast cancer by increasing their presence in vital clinical research.
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced...
The pharma firm plans to use the StudyTeam platform to accelerate development, ease site burdens and improve patient matching for breast cancer studies.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
The pharmaceutical company shares details from an ongoing trial looking into the effectiveness of a pair of drugs on treating triple-negative breast cancer.
The FDA this week released a new draft guidance encouraging the inclusion of male patients in breast cancer clinical trials, the incidence of which has increased approximately 26% over the last 25 years.
Elligo expands its Research Ready network and adds its first oncology practice through a partnership with Austin Cancer Center, which is currently enrolling patients for breast cancer studies.
Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
Caligor Opco LLC is providing regulatory and logistical management for Puma Biotechnology’s expanded access program (EAP) for its investigational breast cancer therapy, neratinib.
BriaCell Therapeutics Corp. has submitted a chemistry, manufacturing and control (CMC) amendment to the US FDA before its planned stem-cell based vaccine trial for late stage breast cancer.
Out-of-place softgel capsules have led to the suspension of manufacturing at a site in France, and Catalent says the problem is almost certainly due to malicious actions.
Lonza shipped a sample batch of a drug for resistant cancers this week and is set produce commercial supplies if the Phase I candidate goes on to be approved says Sunshine Biopharma.
A new formulation of Genetech’s breast cancer drug Herceptin means patients could soon receive treatment via injection, rather than time consuming intravenous drip.
Swiss drug major Roche has called in biomarker testing lab Rules-Based Medicine (RBM) to help give its candidate schizophrenia drugs a commercial edge.
After seven months of offers, refusals and heated exchanges, it
seems an increased offer from Roche has finally persuaded the
powers that be at Ventana to sell up.
Lonza is betting on the growth of antibody-drug conjugates as the
way-of-the-future cancer treatments by moving to large scale
production of the emerging drug class by 2008.
Genentech, the world's second biggest biotech company, has shown a
strong performance in the first quarter while its main rival Amgen
is trying to regain momentum after a difficult year.
GlaxoSmithKline's (GSK) new breast cancer drug has been given the
all clear to be used in the US, with the company expecting European
approval to follow later this year.
BN ImmunoTherapeutics, the US subsidiary of Denmark's Bavarian
Nordic, has started clinical trials of MVA-BN-HER2, a new vaccine
targeting breast cancer.
US researchers have combined cancer drug-carrying liposomes and
heat, which accelerates drug release and delivers 30 times more
drug to tumours, as visualised in vivo using magnetic
resonance imaging (MRI)
Scientists have found a computational method that charts chemical
space in the search for new breast cancer treatments. The technique
has already resulted in the discovery of compounds that have
performed better than current standard...
Findings from new study have offered an innovative profile of an
enzyme that aids tumour growth, which points towards a potential
new target for treatments for ovarian and breast cancers.
